Hiroya Taniguchi
About
Hiroya Taniguchi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine.
According to data from OpenAlex, Hiroya Taniguchi has authored 171 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Oncology, 78 papers in Pulmonary and Respiratory Medicine and 58 papers in Pathology and Forensic Medicine. Recurrent topics in Hiroya Taniguchi's work include Colorectal Cancer Treatments and Studies (93 papers), Gastric Cancer Management and Outcomes (58 papers) and Genetic factors in colorectal cancer (52 papers). Hiroya Taniguchi is often cited by papers focused on Colorectal Cancer Treatments and Studies (93 papers), Gastric Cancer Management and Outcomes (58 papers) and Genetic factors in colorectal cancer (52 papers). Hiroya Taniguchi collaborates with scholars based in Japan, United States and Spain. Hiroya Taniguchi's co-authors include Takayuki Yoshino, Takao Kojima, Junichi Okuda, Makoto Shimazaki, Kota Fujii, Tomoaki Nakajima, Kazunori Ida, Masahide Hamaguchi, Hiroshi Sarui and Noriyuki Takeda and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Annals of Internal Medicine.
In The Last Decade
Hiroya Taniguchi
158 papers receiving 3.1k citations
Hit Papers
Peers
Hiroya Taniguchi
Shannon J. McCall United States
Tushar Patel United States
In Ja Park South Korea
Tadashi Namisaki Japan
Helen H. Wang United States
Michihisa Moriguchi Japan
Mitsuteru Kitade Japan
Kunihiko Izuishi Japan
Francisco Javier Cubero Spain
Kenichi Furihata Japan
Citations per year, relative to Hiroya Taniguchi Hiroya Taniguchi (= 1×)
peers
Shannon J. McCall
Countries citing papers authored by Hiroya Taniguchi
Since
Specialization
Citations
This map shows the geographic impact of Hiroya Taniguchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroya Taniguchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroya Taniguchi more than expected).
Fields of papers citing papers by Hiroya Taniguchi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Hiroya Taniguchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroya Taniguchi. The network helps show where Hiroya Taniguchi may publish in the future.
Co-authorship network of co-authors of Hiroya Taniguchi
This figure shows the co-authorship network connecting the top 25 collaborators of Hiroya Taniguchi. A scholar is included among the top collaborators of Hiroya Taniguchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroya Taniguchi. Hiroya Taniguchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Taniguchi, Hiroya, Takatsugu Ogata, Yuki Matsubara, et al.. (2025). Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5‐Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study. Cancer Medicine. 14(9). e70889–e70889.
2.
Masuishi, Toshiki, Masako Asayama, Hiroyuki Takeda, et al.. (2024). 599TiP PRABITAS study: A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer. Annals of Oncology. 35. S480–S480.
3.
Nakamura, Yoshiaki, Keiji Hirata, Naoya Akazawa, et al.. (2024). Prognostic and predictive value of ctDNA-based MRD and actionable biomarkers in patients with resectable colorectal cancer: CIRCULATE-Japan GALAXY.. Journal of Clinical Oncology. 42(16_suppl). 3609–3609.
4.
Kotani, Daisuke, Hideaki Bando, Hiroya Taniguchi, et al.. (2024). Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703).. Journal of Clinical Oncology. 42(16_suppl). 3585–3585.
5.
Kajiwara, Takeshi, Tomohiro Nishina, Yoshiaki Nakamura, et al.. (2023). Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Cancers. 15(21). 5172–5172.
6.
Le, Dung T., Luis A. Díaz, Tae Won Kim, et al.. (2023). Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164. European Journal of Cancer. 186. 185–195.
7.
Nagai, Sumimasa, Hiroshi Nishihara, Takayoshi Suzuki, et al.. (2022). Recommendations related to the analytical equivalence assessment of gene panel testing. Cancer Science. 113(10). 3282–3290.
8.
Sakamoto, Yasutoshi, Hideaki Bando, Yoshiaki Nakamura, et al.. (2022). Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world Data. Clinical Colorectal Cancer. 22(1). 45–52.
9.
Kawazoe, Akihito, Kota Itahashi, Noboru Yamamoto, et al.. (2021). TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). Clinical Cancer Research. 27(24). 6709–6715.
10.
Chida, Keigo, Akihito Kawazoe, Masahito Kawazu, et al.. (2021). A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. Clinical Cancer Research. 27(13). 3714–3724.
11.
Kagawa, Yoshinori, Élena Elez, Jesús García‐Foncillas, et al.. (2021). Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. Clinical Cancer Research. 27(9). 2515–2522.
12.
Taniguchi, Hiroya, Yoshiaki Nakamura, Daisuke Kotani, et al.. (2021). CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Science. 112(7). 2915–2920.
13.
Sasaki, Akinori, Akihito Kawazoe, Saori Mishima, et al.. (2020). Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open. 5(4). e000775–e000775.
14.
Taniguchi, Hiroya, Takeharu Yamanaka, Daisuke Sakai, et al.. (2020). Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G. Cancers. 12(7). 1715–1715.
15.
Miyo, Masaaki, Takeshi Kato, Takayuki Yoshino, et al.. (2020). Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer. 20(1). 687–687.
16.
Kubota, Yohei, Akihito Kawazoe, Akinori Sasaki, et al.. (2020). The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer. Clinical Cancer Research. 26(14). 3784–3790.
17.
Masuishi, Toshiki, Hiroya Taniguchi, Daisuke Kotani, et al.. (2019). Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. ESMO Open. 4(6). e000590–e000590.
18.
Yaeger, Rona, Daisuke Kotani, Sebastián Mondaca, et al.. (2019). Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer. Clinical Cancer Research. 25(23). 7089–7097.
19.
Taniguchi, Hiroya, Mano Horinaka, Tatsushi Yoshida, et al.. (2012). Targeting the Glyoxalase Pathway Enhances TRAIL Efficacy in Cancer Cells by Downregulating the Expression of Antiapoptotic Molecules. Molecular Cancer Therapeutics. 11(10). 2294–2300.
20.
Taniguchi, Hiroya, Tatsushi Yoshida, Mano Horinaka, et al.. (2008). Baicalein Overcomes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells. Cancer Research. 68(21). 8918–8927.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Shannon J. McCall Breakdown of academic impact, for papers by Tushar Patel Breakdown of academic impact, for papers by In Ja Park Breakdown of academic impact, for papers by Tadashi Namisaki Breakdown of academic impact, for papers by Helen H. Wang Breakdown of academic impact, for papers by Michihisa Moriguchi Breakdown of academic impact, for papers by Mitsuteru Kitade Breakdown of academic impact, for papers by Kunihiko Izuishi Breakdown of academic impact, for papers by Francisco Javier Cubero Breakdown of academic impact, for papers by Kenichi Furihata